ARYx falls on tecarfarin data
09 July 2009
Alex Shimmings
Please Login to read the full article.
09 July 2009
Alex Shimmings
alex.shimmings@informa.com
Disappointing Phase II/III data for ARYx Therapeutics' novel anticoagulant tecarfarin (formerly ATI-5923) have sent the Californian firm's share price tumbling.
The product, one of the company's two lead projects, did not achieve the primary endpoint of superiority over warfarin in the EmbraceAC...
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA advisers back J&J-Bayer stroke drug, but call for warfarin transition testing
- US FDA drug reviewers advise against approval of J&J-Bayer stroke drug
- Bayer must convince NICE it has not overestimated the effectiveness of Xarelto
- BMS/Pfizer's Eliquis better than Lovenox, but comparison with Pradaxa and Xarelto not clear, says NICE
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
